Skip to main content

Table 2 Baseline characteristics of patients with prostate cancer based on mGPS categories

From: The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients

  The modified Glasgow prognostic score (mGPS) P-value
mGPS = 0 mGPS = 1 mGPS = 2
  Patients, n (%) Patients, n (%) Patients, n (%)  
Age at incidence (years)     
   Age < 65 88 (25.29) 71 (21.78) 7 (10.00) 0.014
   Age 65-74 127 (36.49) 112 (34.36) 22 (31.43)
   Age ≥ 75 133 (38.22) 143 (43.87) 41 (58.57)
Gleason score     
   Gleason < 7 95 (27.30) 67 (20.55) 15 (21.43) <0.001
   Gleason = 7 85 (24.43) 51 (15.64) 6 (8.57)
   Gleason 8-10 124 (35.63) 113 (34.66) 25 (35.71)
   Unknown Gleason 44 (12.64) 95 (29.14) 24 (34.29)
SIMD 2006, Quintiles     
   1 (most deprived) 117 (33.62) 128 (39.26) 27 (38.57) 0.219
   2 71 (20.40) 70 (21.47) 9 (12.86)
   3 46 (13.22) 45 (13.80) 9 (12.86)
   4 43 (12.36) 28 (8.59) 13 (18.57)
   5 (least deprived) 71 (20.40) 55 (16.87) 12 (17.14)
Prostate specific antigen (ug/l)     
   PSA < 10 140 (40.35) 99 (30.46) 26 (37.14) <0.001
   PSA 10-20 69 (19.88) 42 (12.92) 4 (5.71)
   PSA > 20 138 (39.77) 184 (56.62) 40 (57.14)
Previous inpatient bed days     
   0 200 (57.47) 174 (53.37) 30 (42.86) 0.022
   1-7 73 (20.98) 65 (19.94) 17 (24.29)
   8-28 55 (15.80) 64 (19.63) 11 (15.71)
   29+ 20 (5.75) 23 (7.06) 12 (17.14)  
\